Your browser doesn't support javascript.
loading
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.
Franssen, Stijn; Holster, Jessica J; Jolissaint, Joshua S; Nooijen, Lynn E; Cercek, Andrea; D'Angelica, Michael I; Homs, Marjolein Y V; Wei, Alice C; Balachandran, Vinod P; Drebin, Jeffrey A; Harding, James J; Kemeny, Nancy E; Kingham, T Peter; Klümpen, Heinz-Josef; Mostert, Bianca; Swijnenburg, Rutger-Jan; Soares, Kevin C; Jarnagin, William R; Groot Koerkamp, Bas.
Afiliación
  • Franssen S; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Holster JJ; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Jolissaint JS; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Nooijen LE; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Cercek A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • D'Angelica MI; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Homs MYV; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Wei AC; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Balachandran VP; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Drebin JA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Harding JJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kemeny NE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kingham TP; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Klümpen HJ; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Mostert B; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Swijnenburg RJ; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Soares KC; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Jarnagin WR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Groot Koerkamp B; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. b.grootkoerkamp@erasmusmc.nl.
Ann Surg Oncol ; 31(1): 115-124, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37814188
ABSTRACT

BACKGROUND:

A post-hoc analysis of ABC trials included 34 patients with liver-confined unresectable intrahepatic cholangiocarcinoma (iCCA) who received systemic chemotherapy with gemcitabine and cisplatin (gem-cis). The median overall survival (OS) was 16.7 months and the 3-year OS was 2.8%. The aim of this study was to compare patients treated with systemic gem-cis versus hepatic arterial infusion pump (HAIP) chemotherapy for liver-confined unresectable iCCA.

METHODS:

We retrospectively collected consecutive patients with liver-confined unresectable iCCA who received gem-cis in two centers in the Netherlands to compare with consecutive patients who received HAIP chemotherapy with or without systemic chemotherapy in Memorial Sloan Kettering Cancer Center.

RESULTS:

In total, 268 patients with liver-confined unresectable iCCA were included; 76 received gem-cis and 192 received HAIP chemotherapy. In the gem-cis group 42 patients (55.3%) had multifocal disease compared with 141 patients (73.4%) in the HAIP group (p = 0.023). Median OS for gem-cis was 11.8 months versus 27.7 months for HAIP chemotherapy (p < 0.001). OS at 3 years was 3.5% (95% confidence interval [CI] 0.0-13.6%) in the gem-cis group versus 34.3% (95% CI 28.1-41.8%) in the HAIP chemotherapy group. After adjusting for male gender, performance status, baseline hepatobiliary disease, and multifocal disease, the hazard ratio (HR) for HAIP chemotherapy was 0.27 (95% CI 0.19-0.39).

CONCLUSIONS:

This study confirmed the results from the ABC trials that survival beyond 3 years is rare for patients with liver-confined unresectable iCCA treated with palliative gem-cis alone. With HAIP chemotherapy, one in three patients was alive at 3 years.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma Límite: Humans / Male Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma Límite: Humans / Male Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos